Filing Details
- Accession Number:
- 0001437749-24-022708
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-07-12 19:38:10
- Reporting Period:
- 2024-07-02
- Accepted Time:
- 2024-07-12 19:38:10
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 907654 | Arca Biopharma Inc. | ABIO | In Vitro & In Vivo Diagnostic Substances (2835) | 363855489 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1274173 | Plc Group Henderson Janus | 201 Bishopgate London X0 EC2M 3AE | No | No | Yes | No | |
| 2030299 | Ltd Fund Master Innovation Biotech Henderson Janus | 201 Bishopgate London X0 EC2M 3AE | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-07-03 | 166,042 | $3.55 | 1,648,577 | No | 4 | P | Indirect | By Fund |
| Common Stock | Acquisiton | 2024-07-05 | 23,326 | $3.43 | 1,671,903 | No | 4 | P | Indirect | By Fund |
| Common Stock | Acquisiton | 2024-07-05 | 5,000 | $3.41 | 1,676,903 | No | 4 | P | Indirect | By Fund |
| Common Stock | Acquisiton | 2024-07-08 | 29,892 | $3.41 | 1,706,795 | No | 4 | P | Indirect | By Fund |
| Common Stock | Acquisiton | 2024-07-08 | 17,600 | $3.54 | 1,724,395 | No | 4 | P | Indirect | By Fund |
| Common Stock | Acquisiton | 2024-07-09 | 16,917 | $3.43 | 1,741,312 | No | 4 | P | Indirect | By Fund |
| Common Stock | Acquisiton | 2024-07-10 | 33,500 | $3.46 | 1,774,812 | No | 4 | P | Indirect | By Fund |
| Common Stock | Acquisiton | 2024-07-10 | 21,963 | $3.46 | 1,796,775 | No | 4 | P | Indirect | By Fund |
| Common Stock | Acquisiton | 2024-07-11 | 94,537 | $3.45 | 1,891,312 | No | 4 | P | Indirect | By Fund |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Indirect | By Fund |
| No | 4 | P | Indirect | By Fund |
| No | 4 | P | Indirect | By Fund |
| No | 4 | P | Indirect | By Fund |
| No | 4 | P | Indirect | By Fund |
| No | 4 | P | Indirect | By Fund |
| No | 4 | P | Indirect | By Fund |
| No | 4 | P | Indirect | By Fund |
| No | 4 | P | Indirect | By Fund |
Footnotes
- The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.
Billionaire Hedge Funds
